What Adalat 5 Treats: Main Uses and Benefits

Adalat 5 is applied across domains where additional symptomatic support is needed, including cardiovascular and vascular contexts. It is relevant for managing systemic high blood pressure (hypertension), Angina Pectoris (chest pain), and symptoms related to heightened physiological activity in the extremities (such as Raynaud’s phenomenon). This medicine helps ease the overall symptom burden associated with systemic imbalance and requires sustained pressure regulation.

The therapeutic purpose is relevant in contexts marked by increased discomfort or tension related to systemic imbalance, which supports the stability of pressure readings and contributes to a reduced risk profile associated with chronic strain. Furthermore, it is applied in addressing symptoms related to physical discomfort like recurrent chest pain. It is relevant for easing symptom clusters that may become intense or disruptive, which may assist with maintaining functional stability and supports general well-being during symptomatic phases.

“The medication is considered relevant for easing symptoms that interfere with daily functioning and is applied in clinical settings that involve acute or unstable symptom patterns.”

It may be applied in clinical settings that involve acute or unstable symptom patterns, such as severe hypertensive episodes, where supportive symptom management is appropriate.

---

Quick Fact: Relief for Vascular Tension Adalat 5 assists with the management of conditions characterized by periods of heightened symptoms related to vascular tension, providing supportive relief against symptoms that create noticeable physiological strain like pain, numbness, and coldness in the extremities. It is commonly used when symptoms become more disruptive, helping patients cope more steadily.

Who Can and Cannot Use Adalat 5?

The population eligibility for Adalat 5 (Nifedipine) is strictly defined by regulatory authorities and centers on age, underlying conditions, and physiological states. Use is approved only for adults aged 18 and over with established indications.

Absolute Contraindications (Must Not Use)

Adalat 5 is formally contraindicated in several populations due to safety concerns defined in official labeling:

• Patients with known hypersensitivity to Nifedipine or any other dihydropyridine.
• Individuals in cardiogenic shock or those with unstable angina pectoris.
• Patients who have experienced an acute myocardial infarction (AMI) within the last four weeks (one month).
• Those taking the strong enzyme inducer Rifampin, as this severely diminishes the drug’s effect.

Population Restrictions

Age Group / Condition	Regulatory Status
Pediatric Population (under 18)	Use Not Established; Not Recommended.
Pregnancy / Breastfeeding	Not Recommended or Contraindicated.
Hepatic Impairment	Caution; requires monitoring and potential dose reduction.
Severe Hypotension	Caution; risk of excessive blood pressure reduction.

Eligibility is defined by regulatory classification, establishing absolute prohibitions, or requiring conditional use and careful monitoring.

Interactions with other medicines and products

The official regulatory profile for Adalat 5 (Nifedipine) documents specific pharmacokinetic and pharmacodynamic interactions that result in formal co-administration restrictions. These constraints are categorized by their effect on systemic drug exposure and combined physiological action.

Pharmacokinetic and Exposure Constraints

The combination with strong metabolic enzyme inducers, such as Rifampicin and the herbal product St. John’s Wort, is contraindicated. This restriction is mandatory because these substances drastically reduce Nifedipine plasma concentrations, which can result in a loss of therapeutic effect. Nifedipine is cleared via the CYP3A4 enzyme system; consequently, co-administration with strong CYP3A4 inhibitors (e.g., certain macrolide antibiotics or azole antifungals) is documented to increase Nifedipine systemic exposure. Conversely, CYP3A4 inducers like Phenytoin significantly reduce exposure. Furthermore, Nifedipine acts as an inhibitor of the P-glycoprotein (P-gp) transporter, which may increase the systemic levels of co-administered P-gp substrates, such as Digoxin.

Pharmacodynamic and Substance Restrictions

The co-administration with other blood pressure-lowering agents, including beta-blockers and diuretics, may lead to documented additive hypotensive effects. A mandatory substance restriction is the avoidance of Grapefruit or Grapefruit Juice, as its consumption is known to increase Nifedipine exposure. For certain surgical procedures involving high-dose Fentanyl anesthesia, a procedural timing rule recommends that Nifedipine be withheld for at least 36 hours. Official documents also note that Nifedipine clearance is decreased in the geriatric population, resulting in a higher systemic exposure.

Mechanism of Action: Nifedipine

The function of Nifedipine (Adalat 5) is defined by its action as an antagonist at the L-type voltage-dependent calcium channels ( Ca^2+ channels). These channels are essential for the contraction process in vascular smooth muscle cells. The antagonistic interaction prevents the flow of extracellular Ca^2+ into the cell's cytosol, directly leading to arterial smooth muscle relaxation (vasodilation) and the suppression of vasospasm.

This widespread vascular relaxation reduces the overall peripheral vascular resistance (PVR), thereby decreasing the afterload—the mechanical impedance against which the left ventricle ejects blood. This systemic mechanical change results in a decrease in arterial blood pressure. Simultaneously, the mechanism acts on the coronary arteries to increase the lumen diameter, enhancing blood delivery to the myocardium and modulating the myocardial oxygen supply-to-demand ratio.

How to Use Adalat 5: Official Administration Guidelines

Adalat 5, which contains Nifedipine, is strictly for oral administration and is manufactured in distinct forms: Immediate-Release (IR) capsules and Extended-Release (ER) tablets. The specific dosage form dictates the administration schedule and required dosage integrity.

---

Standard Dosage and Frequency

Dosage Form	Starting Dose (Typical)	Frequency	Maximum Daily Dose
Extended-Release (ER) Tablet	30 mg or 60 mg	Once Daily	Up to 120 mg
Immediate-Release (IR) Capsule	10 mg	Three Times Daily	180 mg

Maintenance doses are subject to gradual adjustment, typically over intervals of 7 to 14 days. Treatment is generally managed as a long-term protocol.

---

Administration Requirements and Restrictions

To ensure the correct drug release pattern, ER tablets must be swallowed whole with water and must not be broken, crushed, chewed, or divided. While the medicine may be taken with or without food, the administration time should remain consistent each day.

Special procedural conditions for proper use include a restriction on diet: grapefruit or grapefruit juice must be strictly avoided because co-administration can affect the drug's plasma concentration. For specific populations, clinical practice involves dose reduction in cases of hepatic impairment and a lower initial dose for older adults.

Research Evidence / Overview of Studies for Adalat 5

Evidence from Clinical Trials for High Blood Pressure (Hypertension)

Research for Adalat 5 (Nifedipine) in examining high blood pressure, or hypertension, has primarily involved Randomized Controlled Trials (RCTs) and large-scale observational studies. These trials were designed to assess patterns of change in Systolic and Diastolic Blood Pressure (BP) levels in adults with mild to moderate essential hypertension. Studies report that the monitored measurements of both systolic and diastolic blood pressure showed patterns of change across the observed populations.

What remains uncertain is the long-term use of the immediate-release (IR) capsule formulation for chronic care of hypertension. Certain regulatory reviews note that the rapid change in blood pressure associated with the IR form was observed in some early studies to be associated with certain measured patterns that require further review. Because of this, extended-release formulations are more frequently the focus of current long-term research for this condition.

---

Evidence from Clinical Trials for Angina Pectoris (Chest Pain)

The research base for using Nifedipine for Angina Pectoris (chest pain related to effort or vasospasm) also includes Randomized Controlled Trials and Systematic Reviews. These studies focused on outcomes related to physical discomfort and functional imbalance experienced by patients. The outcomes monitored included the frequency of Angina Attacks, the patients' change in activity level (Exercise Tolerance), and the need for sublingual rescue medication.

Findings describe patterns observed in the studies where patients reported a change in the number of chest pain episodes during the treatment period compared to placebo phases. Furthermore, studies report that participants often demonstrated a measurable change in exercise duration, with findings reflecting daily functioning or activity level. Studies report that the data described patterns of change in short-term symptom outcomes and change in exercise tolerance.

---

Evidence from Trials for Raynaud's Phenomenon

Nifedipine was evaluated in research exploring symptoms related to Raynaud’s Phenomenon, a condition involving periods of heightened symptoms. These studies typically employed short-term, double-blind, placebo-controlled crossover designs. Studies monitored patient-reported outcomes describing perceived discomfort and specifically tracked the frequency and severity of symptomatic attacks. Research highlights changes measured during the study period, with findings indicating a pattern of change in attack frequency and symptom intensity when the medication was used, compared to periods of non-active treatment.

A key research limitation is that the available studies are generally short-duration trials, meaning that long-term effects are not fully established regarding the durability of response or whether the medication alters the long-term course of the condition.

---

What is Still Uncertain About Adalat 5 Research

A major point of regulatory discussion is the use of the immediate-release (IR) capsule formulation (like Adalat 5 mg). Findings for this specific formulation were observed in some studies to be associated with rapid physiological changes that were discussed in regulatory reviews as being unsuitable for long-term chronic care. Additionally, follow-up durations were limited in many symptomatic trials, meaning that long-term effects are not fully established.

Common questions about Adalat 5 (FAQ)

---

Q: Is Adalat 5 the same as Adalat CC?

Adalat and Adalat CC are both recognized brand names for the active ingredient Nifedipine. According to official product information, Adalat CC is specifically a controlled-release tablet, which means it is designed to release the medication slowly and steadily over a longer period. This differs from other Nifedipine formulations, which may release the drug more quickly.

---

Q: Can I take Adalat 5 with my regular pain relievers (like ibuprofen or acetaminophen)?

Regulatory-related information indicates that taking Nifedipine with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may cause a change in blood pressure control. Acetaminophen is not specifically highlighted with a major interaction concern in official documents. Information regarding the use of Nifedipine with other medications is included in official product documentation.

---

Q: Is it safe to drink alcohol in moderation while using Adalat 5?

Official drug information notes that alcohol may have an additive effect when combined with Nifedipine in lowering blood pressure. This combination can increase the possibility of certain side effects, such as dizziness, lightheadedness, or headache. Regulatory information describes that consultation regarding alcohol intake is a matter for individual medical assessment.

---

Q: Are there certain supplements or vitamins that interfere with Adalat 5?

Official regulatory documents describe a strict contraindication for the herbal product St. John’s Wort, as it drastically reduces the medication's effectiveness. Additionally, the drug’s intended effect may be decreased when used with supplements containing high levels of calcium or certain multivitamin with mineral products. Such co-administration conditions are documented for review by healthcare professionals.

---

Q: Can Adalat 5 be used by people who have diabetes?

Nifedipine is not formally contraindicated for patients with diabetes in official regulatory documents. However, official information does document a drug-drug interaction when Nifedipine is used alongside the common diabetes medication Metformin, which may increase Metformin levels in the body. The combination of Nifedipine and Metformin is one that official documents state should be considered with caution.

---

Q: Does taking Adalat 5 require any special monitoring or blood tests?

Monitoring includes careful observation of blood pressure during initial treatment. Official information also notes that monitoring of certain lab values may be relevant in specific circumstances or special populations.

---

Q: Are there any reported issues with stopping Adalat 5 suddenly?

Official regulatory warnings do not cite a direct withdrawal syndrome for Nifedipine on its own. However, official information notes that if Nifedipine is stopped while a patient is also taking a beta-blocker, abrupt withdrawal of the beta-blocker may cause issues. Any decision to discontinue Nifedipine should only be made under professional guidance.

---

Q: Is there a generic version of Adalat 5 available?

Yes, the active ingredient in Adalat 5, Nifedipine, has multiple generic versions approved by regulatory bodies like the FDA. These generic formulations are available in both immediate-release and extended-release forms.

---

Q: How is Adalat 5 different from other nifedipine formulations?

Adalat 5 represents a specific commercial formulation of Nifedipine, which is available in immediate-release (IR) or controlled-release (CC/ER) types. Other Nifedipine products may utilize distinct drug delivery systems, such as different types of coatings or mechanisms that control how the medicine is absorbed in the body.

---

Q: Does the time of day matter when taking Adalat 5?

Official administration guidelines state that the time the medication is taken should remain consistent each day. This consistent schedule is the key requirement, particularly for extended-release formulations, which are designed to provide a steady effect over a full 24-hour period.

---

Q: Can Adalat 5 affect kidney function?

Official documents report that Nifedipine has rarely been associated with reversible elevations in specific lab values in patients who had pre-existing chronic kidney issues. Official documentation notes that the use of Nifedipine requires consideration and monitoring in individuals with pre-existing chronic renal insufficiency.

---

Q: Why do doctors prescribe Adalat 5 instead of other available options?

Official documentation describes Nifedipine as belonging to a specific class of medicines called dihydropyridine calcium channel blockers. This class is differentiated by its pronounced and selective action, primarily on the vascular smooth muscle. This unique pharmacological profile is often cited as the rationale for its specific use.

---

Q: What does the term 'sustained-release' mean for Adalat 5?

The term 'sustained-release' (often referred to as 'extended-release' or 'ER') describes a formulation designed to release the active drug, Nifedipine, slowly and continuously into the body over an extended period. This mechanism is intended to maintain a more consistent level of medication throughout the day.

---

Q: Are there any dietary restrictions other than grapefruit when on Adalat 5?

Official guidance strictly prohibits grapefruit or grapefruit juice due to a known interaction. Regulatory information also advises that certain food substances containing calcium, oxalic acid, or phytic acid may potentially interfere with the medication’s effects. These potential interactions are factors for healthcare professionals to review.

---

Q: Can Adalat 5 interact with antacids?

Official documents indicate that the use of calcium-containing antacids may decrease the effectiveness of Nifedipine by reducing how much is absorbed. Additionally, large changes in stomach pH caused by certain strong antacids may alter the release profile of the extended-release formulations.

---

Q: Can Adalat 5 be taken by someone who has asthma?

Nifedipine is not formally listed as being contraindicated in asthma in official prescribing information. While some early research suggested it might influence bronchial tone, the medication is not approved for the treatment of asthma. The suitability of Nifedipine for individuals with asthma is a factor for clinical review.

---

Q: Does Adalat 5 have an impact on heart rate?

Official documents describe that Nifedipine may cause a reflex increase in heart rate (tachycardia) due to its strong blood vessel dilating action, particularly with immediate-release formulations. Extended-release formulations are generally designed to minimize this rapid physiological change.

How to Store and Dispose of Adalat 5

Proper storage and disposal of Adalat 5 (Nifedipine) are mandatory to maintain product stability and ensure household safety, as defined by regulatory labeling.

Storage Requirements

Adalat 5 must be stored at room temperature, generally between 15 C and 25 C (59 F and 77 F), and should not be stored above 30 C. The product must be kept in its original container and protected from strong light and excess moisture. To prevent accidental exposure, the medicine must always be stored out of the sight and reach of children and pets.

Disposal Instructions

Expired or unused Adalat 5 should be safely disposed of. The preferred method is using a drug take-back program or authorized collection site. Since Nifedipine is not on the flush list, it should not be discarded down the sink or toilet. If a take-back site is unavailable, the product must be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash.